Study of Edoxaban for anti-coagulation after Watchman implant

Trial ID:
Matthew J Price, M.D.
This study will evaluate the safety and effectiveness of 6 weeks of anticoagulation therapy with Edoxaban followed by therapy with aspirin and clopidogrel for 6 months in patients who have had a WATCHMAN device implanted for closure of the left atrial appendage (LAA). Patients will have a follow-up visit at 6 weeks post-LAA closure and one follow-up phone call at 6 months.

Inclusion Criteria

  • Have documented non-valvular Atrial Fibrillation
  • Be scheduled or planning to have a WATCHMAN device implanted for LAA closure
  • Meet all other eligibility criteria

Exclusion Criteria

  • Have conditions other than atrial fibrillation that require oral anti-coagulation
  • Have had a stroke within the past 7 days
  • Have a hypersensitivity to edoxaban
  • Have moderate or severe mitral stenosis
  • Be required to take aspirin at a dose of 81mg or more a day
  • Have an unsuccessful LAA closure
  • Be planning to have another surgery or invasive procedure within 6 of enrollment

Additional Info

  • Edoxaban is currently approved by the FDA to prevent blood clots in patients with non-valvular atrial fibrillation, and may have a reduced risk of bleeding compared to other approved drugs.
  • All patients will receive Edoxaban for 6 weeks and if the LAA closure is deemed acceptable, will stop taking edoxaban and will be prescribed aspirin and clopidogrel until their routine 6 month visit.

Contact Info:

  • Heather Catchpole
  • 858-824-4248